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TRADDa b s t r a c t
Death receptor 6 (DR6) is a member of the death domain-containing receptors that belong to the
TNFR superfamily. To date, the ligand for DR6 is still not clearly deﬁned. Here, we developed a func-
tional agonist monoclonal antibody (DQM3) against DR6, which bound to the ﬁrst cysteine-rich
domain. Importantly, DR6 signaling could be clearly activated by DQM3, which was dependent on
its intracellular death domain. In addition, we demonstrated that the association between DR6
and TRADD was enhanced upon DQM3 stimulation and TRADD was involved in DR6-induced signal-
ing activation. Taken together, our ﬁndings provide new insight into a novel mechanism by which
DR6 induces downstream signaling in response to an agonist antibody.
Structured summary of protein interactions:
DR6 physically interacts with TRADD by anti bait coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Death receptors are a subset of the tumor necrosis factor (TNF)
receptor superfamily characterized by the presence of a conserved
death domain (DD) in their cytoplasmic regions [1,2]. There are
eight death receptors which have been identiﬁed in humans,
including TNFR1, Fas (DR2, CD95 or APO-1), DR3, TRAIL-R1
(DR4), TRAIL-R2 (DR5), DR6, p75NTR (NGFR) and EDAR. In addition
to primarily inducing apoptosis, engagement of death receptor un-
der certain circumstances may initiate multiple non-apoptotic sig-
naling pathways, including activation of nuclear factor-jB (NF-jB)
and mitogen-activated protein kinase (MAPK) cascades, which pro-
mote the regulation of cell differentiation, proliferation, cytokine
and chemokine production, and the modulation of immune
responses [3,4].Death receptor 6 (DR6, TNFRSF21) was identiﬁed as a death do-
main-containing receptor and the least characterized member of
the TNFR superfamily [5]. DR6 is widely expressed in human tis-
sues, including lymphoid organs, brain, pancreas and several
non-lymphoid cancer cell lines [5,6]. Upon overexpression in some
cell lines, DR6 was reported to induce apoptosis as well as activa-
tion of NF-jB and c-Jun N-terminal kinase (JNK) pathways [5].
Knockout studies in mice suggest that DR6 serves as an important
regulator for T cell and B cell functions [7–9]. In addition, DR6/
mice were found to be resistant to EAE and allergic airway hyper-
sensitivity [10,11].
It has been recently shown that a cleaved N-terminal fragment
of the b-amyloid precursor protein (N-APP) may act as a ligand for
DR6, triggering axon pruning and neuron death [12]. However, the
N-APP did not bind to DR6 and trigger the activation of NF-jB and
JNK [13]. Moreover, DR6 regulates oligodendrocyte survival, matu-
ration and myelination through a mechanism independent of N-
APP [14]. To date, DR6 still remains as an orphan TNFR superfamily
member and the mechanism by which DR6 induces downstream
signaling is still largely unknown.
In the present study, we prove that the ﬁrst cysteine-rich do-
main of DR6 is responsible for the binding of the agonist antibody
(DQM3) against DR6. Notably, DR6 signaling can be activated by
DQM3. Furthermore, we characterize the death domain of DR6
and the adaptor molecule TRADD involved in DR6 activation.
402 R. Hu et al. / FEBS Letters 588 (2014) 401–4072. Materials and methods
2.1. Reagents and plasmid construction
The full-length DR6 (DR6-FL) and DR6 mutants including extra-
cellular DR6 (DR6-EX), DR6 (1-414), DR6 (1-498), DTRAF (D371-
414) and DDD (D415-498) were cloned into mammalian expres-
sion vector. DR6 mutants DR6DCRD3-4, DR6DCRD2-1, DR6DCRD2,
DR6DCRD1, DR6D67-88 and DR6D50-66 were generated from
pIRES2-EGFP-DR6-FL. A 5 kbp fragment of the human IL-6 gene pro-
moterwas ampliﬁed fromhuman genomic DNA and ligated into the
vector pGL4.20 (Promega). pNF-jB-Luc was purchased from Clon-
tech. The full-length TRADD and dominant negative form of TRADD
(TRADD-DN) lacking the death domainwere epitope taggedwith an
N-terminal Flag tag and cloned into the vector pTT3.
Mouse monoclonal antibodies against human DR6 were gener-
ated using the standard techniques from splenocytes of mice
immunized with the protein DR6-EX fused with human IgG1-Fc
expressed in HEK293T cells. The rabbit polyclonal anti-TRADD
antibody was purchased from Abcam. The mouse monoclonal
anti-Flag M2 antibody was from Sigma. Antibodies against phos-
pho-SAPK/JNK (Thr183/Tyr185) and SAPK/JNK were purchased
from Cell Signaling Technology. Antibody against phospho-IjBa
was obtained from Santa Cruz Biotechnology.
2.2. Cell culture and transfection
The human embryonic kidney cell line HEK293T was cultured in
a 5% CO2 incubator at 37 C with complete DMEM (Gibco) medium
supplemented with 10% fetal bovine serum, 2 mM L-Glutamine and
100 U/ml penicillin/streptomycin. For transfection, HEK293T cells
were transfected with indicated plasmids using the Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s instruc-
tions. Empty vector was used to equalize the total amount of DNA
in all transfections. Subsequently, reporter gene assays, ﬂow
cytometry analysis and co-IP experiments were preformed.
2.3. Flow cytometry analysis
The cells for ﬂowcytometry analysis areharvested and incubated
on ice with blocking buffer for 20 min, and then incubate the cells
withanti-DR6mAbs (5 lg/ml) or isotype control antibodies (BioLeg-
end) on ice for 30 min. Add the PE-conjugated goat anti-mouse IgG
(BioLegend) to the cells and incubate in the dark on ice for 30 min.
Add the viability dye 7-AAD (Invitrogen) to each sample to exclude
dead cells from analysis. Wash the stained cells once and resuspend
in staining buffer prior to ﬂow cytometry analysis on FACSCalibur
(BD Biosciences). Data were analyzed using Summit software.
2.4. Luciferase assay
HEK293T cells in 24-well plates were transiently transfected
with reporter plasmid encoding the ﬁreﬂy luciferase gene under
control of the NF-jB or IL-6 promoter together with various
expression plasmids for DR6 or DR6 mutants. The pRL-TK encoding
Renilla luciferase served as an internal transfection control. Anti-
DR6 mAb was added 24 h after transfection, and isotype control
antibody also served as a negative control. 16 h later, luciferase
activity was measured with the Dual-Luciferase Reporter Assay
System (Promega).
2.5. RNA interference
Double strand siRNA oligonucleotides targeting human TRADD
were purchased from GeneChem (Shanghai, China), and thesequences are: sense, 50-GGAGGAUGCGCUGCGAAAUUU-30; anti-
sense, 50-AAAUUUCGCAGCGCAUCCUCC-30 [15]. The siRNA with a
scrambled sequence was used as a negative control. HEK293T cells
were transfected with siRNA using Lipofectamine 2000 according
to the manufacturer’s instructions.
2.6. Co-immunoprecipitation and Western blot analysis
For co-immunoprecipitation, 2  106 of HEK293T cells were
transfected with the indicated expression plasmids for DR6-FL or
DR6-EX and ﬂag-tagged TRADD. 24 h later, anti-DR6 mAb was
added for stimulation for the indicated times. After treatment, cells
were washed twice with cold PBS and then lysed for 30 min on ice
in 500 ll of lysis buffer. The lysates were precipitated with anti-
DR6 mAb overnight at 4 C. Then, Protein G beads (GE Health) were
added and incubated for 4 h at 4 C under gentle rotation. The
beads were washed ﬁve times with lysis buffer and eluted by boil-
ing the beads for 5 min in 2  SDS loading buffer. The eluted pro-
teins were separated by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred to PVDF membranes followed by
immunoblot analysis with the indicated antibodies.
2.7. Statistical analysis
GraphPad Prism software was used for statistical analysis. All
samples were performed in at least duplicate, with each experi-
ment repeated at least three times. Data are shown as
means ± standard errors of mean (S.E.M.) of three independent
experiments. Differences between groups were determined using
an unpaired, two-tailed, Student’s t test. P-values < 0.05 (⁄),
P < 0.01 (⁄⁄) and P < 0.001 (⁄⁄⁄) were considered statistically
signiﬁcant.3. Results
3.1. DR6 induces the activation of NF-jB
In addition to inducing apoptosis in some cell lines, DR6 was
also reported to induce NF-jB activation [5]. Overexpression of
death receptors can mimic ligand activation and trigger receptor
activation and downstream signaling events. Consistent with pre-
vious observation, we found that in transfection studies, DR6-FL in-
duced NF-jB activation in a dose dependent manner, but DR6-EX
lacking the intracellular domain did not (Fig. 1A). IL-6 represents
a pleiotropic inﬂammatory cytokine, which is predominantly regu-
lated by NF-jB. We wondered whether DR6 could induce the acti-
vation of target gene regulated by NF-jB. As shown in Fig. 1B,
overexpression of DR6-FL resulted in signiﬁcantly upregulation of
IL-6 luciferase activity (up to 6-fold) in a dose dependent manner.
However, in contrast to DR6-FL, DR6-EX had no obvious effect on
IL-6 activation, indicating that DR6-induced downstream signaling
activation is dependent on cytoplasmic domain.
3.2. DR6 mAbs bind to different antigenic epitopes in CRD domain
Although the N-APP has been reported to function as a DR6 li-
gand, triggering axon pruning, neuron death and axonal degenera-
tion, results from two other groups indicate that the N-APP may
not activate DR6 in other cell types [13,14]. Accordingly, we also
demonstrated that N-APP had no effect on DR6-induced NF-jB
and IL-6 activation in HEK293T cells (data not shown). Therefore,
we generated three monoclonal antibodies (DQM2, DQM3 and
DQM5) against DR6, which could bind HEK293T cells transfected
with DR6-FL (Fig. 2A).
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Fig. 1. Overexpression of DR6 induces NF-jB and IL-6 activation. (A) HEK293T cells were transiently transfected with NF-jB promoter-driven luciferase reporter plasmid
alone or together with increasing amounts of expression vectors for DR6-FL or DR6-EX. Renilla was co-transfected as an internal transfecion control. Promoter activity was
measured 24 h post transfection by luciferase assay. (B) Similar assay was done with IL-6 reporter plasmid. Data are shown as the mean ± S.E.M. Representative results from
at least three independent experiments are shown.
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cysteine-rich domains (CRDs) and a stalk region in the extracellular
portion [16]. To investigate the binding sites of anti-DR6 mAbs, we
constructed a set of DR6 mutants with deletion of certain extracell-
uar domains (Fig. 2B). As shown in Fig. 2C, in ﬂow cytometry anal-
ysis with HEK293T cells expressing DR6 mutants, all three mAbs
could still bind DCRD3-4, but not DCDR1-2 (top two panels). Addi-
tionally, we found these mAbs could bind DCDR2, but not DCDR1

















Fig. 2. Mapping binding epitopes of anti-DR6 mAbs. (A) HEK293T cells were transiently
cells were indicated by the expression of GFP. DR6 expression was analyzed by ﬂow cyto
EV, empty vector; black line, anti-DR6 mAbs; grey ﬁll, isotype control antibodies. (B) Sch
domain is not shown). The tested DR6 deletion mutants targeting extracellular domain
mutants were transfected into HEK293T cells. Cells were collected after 36 h, and FACS
representative of three independent experiments.located on CDR1. To narrow down the binding sites of these mAbs,
further studies showed that DQM3 and DQM5 could still bind
DR6D67-88, while DQM2 could not (ﬁfth panel). It was worth to
point out that the mutant DR6D67-88 severely decreased the cell
surface localization of DR6 and led to its intracellular retention
(data not shown). Moreover, all three anti-DR6 mAbs could not
bind DR6D50-66 (bottom panel). Additionally, the deletion of stalk
region between CRDs and the transmembrane domain did not af-




























transfected with empty vector or expression vector encoding DR6-FL. Transfected
metry with anti-DR6 mAbs (DQM2, DQM3 and DQM5) or isotype control antibodies.
ematic representation of the DR6 deletion mutants used in this study (intracellular
include DCRD3-4, DCRD1-2, DCRD2, DCRD1, D67-88 and D50-66. (C) DR6 and its
analysis was performed to detect the binding of DQM2, DQM3 and DQM5. Data are
404 R. Hu et al. / FEBS Letters 588 (2014) 401–407demonstrate that all three antibodies bind to the CRD1 of DR6, and
the binding sites of DQM3 and DQM5 are located on amino acids
50-66 of CRD1.
3.3. DQM3, but not DQM2 and DQM5, activates DR6 downstream
signaling
We next asked whether DR6 could induce increased activation
of downstream signaling upon anti-DR6 mAbs stimulation, and
we sought to compare the effects of three anti-DR6 mAbs on
DR6-induced signaling activation by reporter gene assays. As
shown in Fig. 3A, only DQM3 could upregulate IL-6 promoter-dri-
ven luciferase activity, while DQM2 and DQM5 could not. In addi-
tion, DR6-induced IL-6 promoter activation was shown in a dose-
dependent manner in response to DQM3 stimulation (Fig. 3B).
These results indicate that the DQM3 may serve as an agonist anti-
body speciﬁc to DR6, which will be used in further dissecting the
downstream signaling of DR6.
To further understand the potential mechanism through which
DR6 mediates downstream signaling, we next examined the im-
pact of DR6 on NF-jB and JNK activation. DR6-FL induced activa-
tion of both JNK and NF-jB, as indicated by the phosphorylation
of JNK and NF-jB inhibitor IjBa (Fig. 3C). However, DR6-EX
showed considerably impaired induction of NF-jB, but not JNK
activation (Fig. 3C and Supplementary Fig. 1A), suggesting that
DR6-induced NF-jB activation is intracellular domain dependent,
whereas JNK activation is not. Furthermore, DQM3 stimulation
could enhance DR6-induced NF-jB activation (Fig. 3D, third panel).
In contrast, the JNK pathway was not affected upon ligation of
DQM3, as demonstrated by the similar level of phosphorylated
JNK (Fig. 3D and Supplementary Fig. 1B).A 
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Fig. 3. DQM3 stimulates DR6-induced IL-6 luciferase activity. (A) HEK293T cells were co-
DQM3 and DQM5, 10 lg/ml) were added 24 h after transfection, and isotype control an
measure promoter activity after 16 h of antibody incubation. (B) Transfected cells in
determined as described in (A). (C) HEK293T cells were transfected with increasing am
subjected to Western blot analysis using antibodies to phospho-JNK, total JNK and phosph
were left untreated or treated with DQM3 (10 lg/ml) for the indicated times. Western blo
independent experiments.3.4. Death domain is essential for DR6-induced signaling upon the
agonist antibody stimulation
The death domain is an essential protein-binding domain that
accounts for the ability of TNFR1 to induce the activation of the
NF-jB pathway and activation of the apoptotic caspase cascade
[17]. In order to investigate the mechanism by which DR6 trans-
mits signals upon the agonist antibody stimulation, a panel of
DR6 mutants were constructed (Fig. 4A and Supplementary
Fig. 2). They were designed to delete large portions of DR6 intracel-
lular domains responsible for cytosolic signal propagation. Signal-
ing activation induced by DR6 truncations was assessed by
luciferase reporter assay. In response to DQM3 stimulation, DR6-
FL resulted in a 3.6-fold increase of IL-6 promoter activity over re-
moval of cytoplasmic domain (DR6-EX) (Fig. 4B). In contrast to
DR6-EX, DR6 (1-414) had no effect on induction of IL-6 activity
in cells treated with DQM3. However, removal of the N-terminal
fragment following DD termed DR6 (1-498), and deletion of the
TNFR-associated factor (TRAF) binding motif (DTRAF) had almost
the same ability as DR6-FL to induce IL-6 promoter activation upon
DQM3 stimulation (Fig. 4B). Interestingly, deletion of the DD
(DDD) showed considerably impaired induction of IL-6 promoter
activity comparing to DR6-FL. These results suggest that death do-
main is essential for DR6-induced downstream signaling upon the
agonist antibody stimulation.
3.5. TRADD is involved in DR6-induced signaling activation
Ligation of TNFR1 by TNF recruits the TNFR associated death do-
main (TRADD), which serves as the adaptor protein [17]. Pan et al.
have demonstrated that DR6 doesn’t interact with the adaptor−tor + − − − −−
+ FL − + + + + + 
0.3 1 3 10 30−−M3 (μg/ml)





transfected with DR6-FL, IL-6 luciferase reporter and Renilla. Anti-DR6 mAbs (DQM2,
tibody alone also served as a negative control. Luciferase assays were performed to
(A) were stimulated with increasing amounts of DQM3. Luciferase activity was
ounts of vectors for DR6-FL or DR6-EX. 36 h later, cell lysates were prepared and
o-IjBa. b-Actin was used as loading control. (D) Cells transfected with DR6-FL in (C)
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Fig. 4. Death domain is essential for DR6-induced signaling upon DQM3 stimulation. (A) Schematic representation of DR6 mutants used in this study. The deletion mutants
targeting intracellular domain include DR6-EX (1-370), DR6 (1-414), DR6 (1-498), DR6-DTRAF (D371-414) and DR6-DDD (D415-498). (B) HEK293T cells were transfected
with IL-6 reporter plasmid alone or together with a series of expression vectors encoding DR6 or its mutants as indicated above. 24 h later, cells were stimulated with DQM3
or isotype control antibody. Cell lysates were prepared 16 h after antibody incubation and relative luciferase activity of stimulus versus control was calculated as the
mean ± S.E.M. Similar results were obtained in three independent experiments. ⁄⁄⁄P < 0.001; ⁄⁄P < 0.01; N.S., not signiﬁcant.
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ever, whether TRADD is involved in DR6 signaling is still unknown.
We showed that transfection of TRADD alone resulted in induction
of IL-6 promoter activity, but TRADD-DN did not (Fig. 5A). Further-
more, in cells with co-transfection of DR6 and TRADD, the IL-6 pro-
moter activity increased signiﬁcantly up to 6-fold over transfection
of DR6 alone, but the cells co-transfected with DR6 and TRADD-DN
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Fig. 5. TRADD is involved in DR6-induced IL-6 activation. (A and B) HEK293T cells were t
expression vectors for TRADD or TRADD-DN (A) or together with DR6-FL (B). 24 h later
transfeced with IL-6-Luc, Renilla, DR6-FL and TRADD as described in (B), and then stimula
co-transfected with TRADD siRNA (si-TRADD) or negative control siRNA (si-NC) and e
efﬁciency of siRNA. (E) TRADD siRNA-treated cells were transfected with IL-6 reporter pla
for 16 h, and then luciferase activity was monitored as described above. Results are shoactivity could not be further upregulated upon DQM3 stimulation,
suggesting TRADD was sufﬁcient for the signaling pathway in-
duced by DR6 (Fig. 5C).
To bolster the above ﬁndings, we examined whether TRADD
deﬁciency had effects on DR6-induced signaling activation. We
used siRNA targeting TRADD to suppress its expression in HEK293T
cells (Fig. 5D) and then examined the ability of DR6 to activate IL-6
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ransiently transfected with IL-6 reporter plasmid, Renilla and increasing amounts of
, promoter activity was measured by luciferase assay. (C) HEK293T cells were co-
ted with DQM3. 16 h later, luciferase activity was measured. (D) HEK293T cells were
xpression plasmid for TRADD. Western blot analysis was performed to verify the
smid and DR6-FL. 24 h after transfection, cells were subjected to DQM3 stimulation
wn as the mean ± S.E.M. ⁄P < 0.05; ⁄⁄P < 0.01.
406 R. Hu et al. / FEBS Letters 588 (2014) 401–407Fig. 5E, silencing the expression of TRADD could signiﬁcantly
inhibit the DR6-induced IL-6 promoter activity in cells treated with
control antibody or DQM3. The effect of DQM3 ligation on siRNA-
control group (1.6-fold) was comparable to that of siRNA-TRADD
group (1.4-fold). These data further support our conclusion that
TRADD is critically involved in DR6 signaling both in the presence
and absence of DQM3.
3.6. TRADD is a putative adaptor molecule in DR6 downstream
signaling
Previous studies demonstrate that TRADD is a crucial signal
adaptor molecule that mediates intracellular responses from
TNFR1 [18,19]. To further investigate a potential role for TRADD
in DR6 signaling, we sought to conﬁrm the possible interaction of
DR6 with TRADD by co-immunoprecipitation. As shown in
Fig. 6A, TRADD was only co-immunoprecipitated with DR6 in cells
induced for DR6-FL expression (lane 3, second panel), but not in
cells with induction of DR6-EX expression (lane 4). These data sug-
gest that DR6 interacts with TRADD in HEK293T cells.
It has been shown that the death domain-containing C-termi-
nus of TRADD (195-312) was essential and sufﬁcient for interac-
tion with the DD of TNFR1 and induction of apoptosis and NF-jB
activation [17]. To further validate the interaction of TRADD with
DR6, HEK293T cells were transfected with DR6 and TRADD or
TRADD-DN, and the association was determined as described
above. As shown in Fig. 6B, the results demonstrated that TRADD,
but not TRADD-DN co-immunoprecipitated with DR6 (compare
lane 1 with lane 2, second panel), indicating that the DD of TRADD
was necessary for the interaction between DR6 and TRADD.
Next, we asked whether DQM3 could enhance the association
between DR6 and TRADD. As shown in Fig. 6C, the time courseC 
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Fig. 6. DR6 interacts with TRADD in co-immunoprecipitation assays. (A and B) HEK293
TRADD-DN were harvested 48 h after transfection. Total cell lysates were immunoprecip
(B). Western blot analysis of DR6, TRADD and Flag was performed on whole cell lysates as
DR6-FL and Flag-tagged TRADD, and then stimulated or not with DQM3 for the indicated
co-immunoprecipitation. The immunoprecipitates and cell extracts were analyzed by i
shown. b-Actin was used as loading control for each fraction. ⁄, Heavy chain (DQM3); IPstudy indicated that DR6–TRADD interaction could be enhanced
as soon as 15 min of DQM3 stimulation (second panel). Taken to-
gether, these ﬁndings demonstrate that there is a possibility that
TRADD serves as an adaptor molecule that mediates DR6 down-
stream signaling.
4. Discussion
Death receptor 6, characterized by the intracellular death do-
main, belongs to the TNF receptor superfamily. DR6 has been
shown to play an apparent role in regulating transcription factor
activation, apoptosis, maturation and immune responses. Upon li-
gand binding and activation, members of the death receptor family
trigger different signaling pathways. Previous studies demonstrate
that DR6 is highly expressed in human brain and it has been shown
to induce axon pruning, neuron death and axonal degeneration
through binding to its recently described ligand N-APP [12]. How-
ever, Klíma and colleagues showed that N-APP could not bind to
DR6 and mediate the activation of NF-jB and JNK [13]. In particu-
lar, a recently published report proposed a potential role of DR6 in
the regulation of oligodendrocyte survival, maturation and myeli-
nation through a mechanism independent of N-APP [14]. We also
found that N-APP had no effect on DR6-induced NF-jB and IL-6
promoter activation, and it was difﬁcult to deﬁnitively address
the molecular signaling mechanisms of this receptor. Thus, we
generated a functional agonist antibody against DR6, which could
serve as a useful tool in the studies on DR6-induced signaling path-
ways. Importantly, we showed that DR6 signaling could be clearly
activated by this agonist antibody, which was dependent on the
death domain.
Upon binding of their speciﬁc ligands, DD-containing adaptor
proteins are recruited by death receptors leading to the assemblyB 
Flag-TRADD-DN − + + + 
DR6-FL + + − −
DR6-EX − − + −
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T cells in 60-mm dishes co-transfected with DR6-FL/EX and Flag-tagged TRADD or
itated with anti-DR6 (DQM3) and immunoblotted with anti-TRADD (A) or anti-Flag
a control (Input). (C) HEK293T cells were co-transfected with expression vectors for
times. The interaction of TRADD with DR6 was assessed after DQM3 stimulation by
mmunoblot. Results representative of at least three independent experiments are
, immunoprecipitates; IB, immunoblot.
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signal-transducing proteins. It has been demonstrated that TRADD,
the ﬁrst protein recruited to TNFR1, serves as a central adaptor to
recruit additional mediators such as the serine/threonine kinase
RIP and TRAF2, activating NF-jB and JNK survival pathways
[17,20,21]. We hypothesized it was likely that DR6 mediated
downstream signaling using a similar mechanism as TNFR1. In this
study, we showed that TRADD was also involved in DR6-induced
signaling, which was signiﬁcantly inhibited when the expression
of TRADD was silenced (Fig. 5E). To further dissect the role of
TRADD in DR6-induced signaling activation, we conﬁrmed the
physical interaction of DR6 with TRADD. Nevertheless, further
studies are still needed to discover other unknown mediators in-
volved in DR6 signaling.
Mimicking ligand induced receptor activation by overexpress-
ing DR6 in some cell lines such as HeLa and HEK293 cells demon-
strated that DR6 could induce apoptosis. Moreover, DR6-induced
apoptosis was independent of FADD and could be inhibited by
the caspase inhibitor Z-VAD [22]. Recently, it has been shown that
DR6 induces apoptosis not through type I or type II pathways of
Fas-mediated apoptosis, but via a unique pathway that exclusively
depends on the mitochondrial pathway and probably through
interacting with Bax [23]. In our study, we found that DR6 induced
more cell death if co-transfeced with TRADD or stimulated with
the agonist antibody in HEK293T cells (data not shown).
Various types of cancer cells express death receptors and activa-
tion of them on tumor cells by agonists can exert antitumor activ-
ity [24]. Wilson et al. detected DR5 expression in tumor endothelial
cells, and treatment of tumor-bearing mice with DR5 ligand in-
duced apoptosis, which disrupts the integrity of tumor blood ves-
sels and decreases tumor growth [25]. DR6 is highly expressed on
many tumor cell lines and clinical tumor samples [5,22,26]. There-
fore, DR6 signaling may play a crucial role in tumorigenesis by
affecting the generation of anti-tumor activity. Understanding
the mechanism of DR6-induced signaling pathway makes DR6 to
be a potential therapeutic target for treating inﬂammatory and
autoimmune disease or cancer [27,28].
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